NCT06952101Recruiting
A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
INTERPRETE: a Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
A phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage. The study investigates and may propose a comprehensive, stage-specific, multimodal approach to rectal adenocarcinoma, with a focus on organ preservation even in early stages (cT1-2N0). When organ-sparing strategies are not feasible, the approach prioritizes minimally invasive techniques (laparoscopic and robotic) to reduce the physical, psychological, and quality-of-life impact on patients.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 20 Feb 2025
- Start date
- 30 Apr 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Fondazione del Piemonte per l'Oncologia
- Diseases
- Colorectal cancer
- NCT number
- NCT06952101
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 30 Apr 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- cT2-4 any NM0 who don't reach cCR or cMR after experimental/standard CRT
- Pregnancy
Who the study is looking for
- Patients aged ≥18 yrs old
- Patients able to sign the informed consent
- Patients with High Risk pT1 rectal adenocarcinoma endoscopically excised
- Patients with cT2-3aN0 rectal adenocarcinoma who has complete/major response to EXPERIMENTAL CRT
- Patients with cT3b4N0-1 rectal adenocarcinoma who has complete/major response to STANDARD CRT
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Surgical Oncology - FPO-IRCCS Institute for Cancer Research and Treatment Coordinator of this site? Confirm its status | Candiolo | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.